Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo
about
Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1.Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence.Suppressor role of activating transcription factor 2 (ATF2) in skin cancerThe prolyl isomerase Pin1 in breast development and cancerSignalling in the epidermis: the E2F cell cycle regulatory pathway in epidermal morphogenesis, regeneration and transformationRAS oncogenes: weaving a tumorigenic webCyclins: roles in mitogenic signaling and oncogenic transformationThe p53-dependent effects of macrophage migration inhibitory factor revealed by gene targetingLoss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesisSPIN90 knockdown attenuates the formation and movement of endosomal vesicles in the early stages of epidermal growth factor receptor endocytosis.A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling.ETS-targeted therapy: can it substitute for MEK inhibitors?Insights into cancer from transgenic mouse models.Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesisA new functional classification of tumor-suppressing genes and its therapeutic implications.pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway.A novel role for integrin-linked kinase in epithelial sheet morphogenesisThe thyroid hormone receptors modulate the skin response to retinoidsLoss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes.Specific protection against breast cancers by cyclin D1 ablation.Paradigms of growth control: relation to Cdk activation.Inhibition of tumor growth and metastasis by non-small cell lung cancer cells transfected with cyclin D1-targeted siRNAThe mammalian Jun proteins: redundancy and specificity.Surprising dependency for retinoblastoma protein in ras-mediated tumorigenesisSignaling networks that link cell proliferation and cell fate.Cyclin T1 overexpression induces malignant transformation and tumor growth.Cell cycle dysregulation in oral cancer.A mouse model of human oral-esophageal cancer.The thyroid hormone receptors as modulators of skin proliferation and inflammationCyclin D1 governs adhesion and motility of macrophages.Alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis.Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation.Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation.Combined effect of cyclin D3 expression and abrogation of cyclin D1 prevent mouse skin tumor developmentCdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.Cyclin D2 overexpression in transgenic mice induces thymic and epidermal hyperplasia whereas cyclin D3 expression results only in epidermal hyperplasia.IκB kinase alpha and cancerHIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesisThe requirement for cyclin D function in tumor maintenance.
P2860
Q24535558-86BCB6EB-9A9B-4E65-9905-020E3349F867Q24540051-9ED7B052-6B19-41E8-B8AB-DD98200B0B6DQ24652406-65FE151D-1B9A-4CDF-A1BD-67616E039D0CQ24795560-04389889-425C-4CA0-AF4C-25EB145024E2Q24810136-01D07985-D08D-40A6-B3EF-35C27D7B3592Q28250360-02D9E99D-D1BA-4FC2-93E7-605EA352B6CEQ28289852-B8264FAB-47D0-437C-B46B-A5F6159DB694Q28588064-1AB90696-26EB-4592-8BC8-3ED1B52AA6D9Q28594871-88A6D359-49D8-43B5-B6C8-F0509E160185Q30009512-27F5B154-CC89-44C9-855B-B6D92981215BQ30828170-77F571F0-3BAE-4ACF-AA4F-ADFE0A51B661Q33638827-98E571D4-133C-4DA3-819D-6B96BA848FF4Q33643327-74044B2B-1487-4968-9081-C4CF6863E9E5Q33810358-F3A08DE1-1DAC-4B99-B0CC-598472224F1CQ33843457-9F189915-E04E-4F89-AB72-BD0E03524E9CQ33854336-E5E08AB8-4499-4EAB-B0A9-9F7CEC711A39Q33872322-D9884AC0-67A1-45B8-8705-13AF9231C6D4Q33938365-54F545D9-8E37-4B1C-9A26-B99481183FFCQ34000076-1BC2C365-D930-473B-BACB-FAED141809C6Q34009230-E366F1FD-1DBB-4E31-BA1C-38F1AC16BF78Q34082446-5DE93CB5-B2CD-4905-A4EC-0F817F437EAAQ34130676-050202D9-5133-40BB-8004-3E8B071A8EFBQ34167898-CDE649AF-F692-4C47-B3F9-4D662A2AE639Q34279339-649CD0C4-C0F2-43DE-9F59-64CA22F7CBDCQ34353737-EE6C4EB1-48CF-48A4-8377-AE6642A3B5C0Q34502845-69012DEA-2C23-40CD-9C8F-717DF712732AQ34582060-D434678B-C497-4CB2-BBE7-091625EAB981Q34720567-E3719708-B089-4A20-8CE2-96E9C3745488Q34796816-AC339A95-7FE6-4E68-86C0-187149EFEC0CQ35085091-6BDA4DF3-6A50-4691-A1B9-5F84E8A05591Q35153599-B9F0BC9B-547F-4B62-8C77-662375895AC8Q35154879-9DB0883D-0DB0-4433-A31A-D33DA516E782Q35747628-0E3C95F6-19DF-4E84-8E9D-6346886DA0D5Q35792968-39735A4C-0F52-4C3F-9BC9-BFF1EDB74C19Q35801403-A7B58FD6-6485-4303-B2DD-195F008E9108Q35805158-B3858EE3-45CD-4B0D-9F0F-7B1450A58FBCQ35829500-61123421-1415-460E-8DC6-166F73618365Q35872007-F82EEEF0-BA6E-42DF-8840-92A8C3E5DC32Q35919080-01B93871-302E-44A7-95CB-32BC23D2E7ACQ36366702-8763D482-387D-47AB-8512-D2AA6357F70F
P2860
Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo
description
1998 nî lūn-bûn
@nan
1998 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Reduced skin tumor development ...... oncogenic ras pathway in vivo
@ast
Reduced skin tumor development ...... oncogenic ras pathway in vivo
@en
type
label
Reduced skin tumor development ...... oncogenic ras pathway in vivo
@ast
Reduced skin tumor development ...... oncogenic ras pathway in vivo
@en
prefLabel
Reduced skin tumor development ...... oncogenic ras pathway in vivo
@ast
Reduced skin tumor development ...... oncogenic ras pathway in vivo
@en
P2093
P2860
P356
P1433
P1476
Reduced skin tumor development ...... oncogenic ras pathway in vivo
@en
P2093
A I Robles
M L Rodriguez-Puebla
P Sicinski
R A Weinberg
R W Tennant
P2860
P304
P356
10.1101/GAD.12.16.2469
P577
1998-08-01T00:00:00Z